We are excited to announce the commencement of our pivotal Phase 3 clinical study of Ovaprene, an investigational hormone-free monthly intravaginal contraceptive.December 4, 2023/in News/by Jeffrey Oliver /wp-content/uploads/2019/07/dare_logo.svg 0 0 Jeffrey Oliver /wp-content/uploads/2019/07/dare_logo.svg Jeffrey Oliver2023-12-04 10:27:302023-12-08 10:28:06Pivotal Phase 3 clinical study of Ovaprene Announced